Über den Autor
Ronald M Bukowski MD
Emeritus Staff Physician
Cleveland Clinic Taussig Cancer Center
Professor Emeritus of Medicine
CCF Lerner College of Medicine of CWRU
Robert Figlin MD
Professor of Medicine and Biomedical Sciences
Director, Division of Hematology Oncology
Department of Medicine, Cedars-Sinai Medical Center
Associate Director for Academic Programs
Samuel Oschin Comprehensive Cancer Institute
Professor Emeritus of Medicine and Urology
David Geffen School of Medicine at UCLA
Robert Motzer MD
Department of Medicine
Memorial Sloan-Kettering Cancer Center
Professor of Medicine
Weil Medical College of Cornell University
Table of Contents
"Renal Cell Carcinoma: Molecular Targets & Clinical Applications, 3rd Edition"
Editors: Ronald M. Bukowski, M.D., Robert Figlin, M.D., Robert Motzer, M.D.
Ch. 1: Targeted Therapy for Metastatic Renal Cell Carcinoma : the First Ten Years
Ronald M. Bukowski, M.D., Robert Figlin, M.D., Robert Motzer, M.D.
Ch. 2: RCC: Pathologic and Molecular assessment of Targets
Ferran Algaba, M.D.
Ch. 3: Targeted Therapy for Metastatic Renal Cell Carcinoma : the First Ten Years
Stephen M. Keefe, M.D., W. Kimryn Rathmell, M.D., Ph.D., Katherine L. Nathanson, M.D.
Ch. 4: VHL and HIF in clear cell Renal Cell Carcinoma: Molecular Abnormalities and Potential Clinical Applications
Lucy Gossage, M.R.C.P., M.Sc.
Ch. 5: PBRM1: A Critical Subunit of the SWI/SNF Chromatin Remodeling Complex
Chung-Han Lee, M.D., Ph.D., Can G. Pham, Ph.D., James J. Hsieh, M.D., Ph.D.
Ch. 6: Sporadic RCC - Abnormalities in Histone Modifying Genes
Ruhee Dere, Ph.D., Thai H. Ho, M.D., Ph.D.
Ch. 7: Genetic Heterogeneity in Renal Cell Carcinoma: Clinical Implications?
Susan A.J. Vaziri, Ph.D, Mahrukh K. Ganapathi, Ph.D, Ram N. Ganapathi, Ph.D.
Ch. 8: First-Generation Tyrosine Kinase Inhibitors - Clinical Results
Han Hsi Wong, Ph.D. Tim Eisen, Ph.D., F.R.C.P.
Ch. 9: Second Generation Tyrosine Kinase Inhibitors (Pazopanib) in Renal Cell Carcinoma: Current Status
Linda Cerbone, M.D., Cora N. Sternberg, M.D., F.A.C.P.
Ch. 10: Third Generation TKIs (Axitinib, Tivozanib) in RCC: enhanced efficacy and diminished toxicity?
Hui Zhu, M.D., Ph.D., Brian I. Rini, M.D. F.A.C.P.,
Ch. 11: Anti-VEGF and VEGFR monoclonal antibodies in RCC
Bernard Escudier, M.D., Laurence Albiges, M.D.
Ch. 12: PI3-Kinase, Akt, and mTOR Inhibitors in RCC
Daniel C. Cho, M.D., James W. Mier, M.D.
Ch. 13: Carbonic anhydrase IX & Monoclonal Antibody G250: relevance as a clinical and biologic target in Renal Cell Carcinoma
Egbert Oosterwijk, Ph.D., Otto C. Boerman, Ph.D., Jeannette C. Oosterwijk-Wakka, B.Sc. Wim J. Oyen, M.D., Ph.D., Peter F. A. Mulders, M.D., Ph.D.
Ch. 14: EGFR and HER2: Relevance in Renal Cell Carcinoma
Sarathi Kalra, M.D., Eric Jonasch, M.D.
Ch. 15: The Role of Hepatocyte Growth Factor Pathway Signaling in Renal Cell Carcinoma
Fabiola Cecchi, Ph.D., Young H. Lee, Ph.D., Benedetta Peruzzi, Ph.D., Jean-Baptiste Lattouf, M.D. Donald P. Bottaro, Ph.D.
Ch. 16: Development of Resistance to Targeted Therapy: Preclinical Findings and Clinical Relevance
James W. Mier, M.D., Rupal S. Bhatt, M.D., Ph.D., David J. Panka, Ph.D., Michael B. Atkins, M.D.
Ch. 17: Development of Combination Therapy with Targeted Agents
C. Lance Cowey, M.D., Thomas E. Hutson, D.O., Pharm.D., F.A.C.P.
Ch. 18: Side Effects of Targeted Thearpy
Luis Leon, M.D., Luis Miguel Anton Aparicio, M.D., Emilio Esteban Gonzalez, M.D., Martin Lazaro Quintela, Ph.D., Sergio Vazquez Estevez, M.D.
Ch. 19: The Role of Targeted Therapy in Special Populations
James M.G. Larkin, Ph.D., F.R.C.P., Martin E. Gore, Ph.D., F.R.C.P.
Ch. 20: Immunotherapy: the Current Role of Cytokines
Mayer Fishman, M.D., Ph.D.
Ch. 21: Immune Checkpoint Inhibitors (anti-CTLA4, anti PD-1) in RCC
David F. McDermott, M.D., Alexandra Bailey, M.D.
Ch. 22: Vaccines in RCC: Clinical and Biological Relevance
Devin B. Lowe, Ph.D., James H. Finke, Ph.D., Jorge A. Garcia, Walter J. Storkus, M.D.
Ch. 23: Development and Incorporation of Biomarkers in RCC Therapeutics
Sumanta K. Pal, M.D., Robert A. Figlin, M.D.
Ch. 24: Molecularly Targeted Staging Strategies in Renal Cell Carcinoma
Steven G Koopman, M.D., Ali-Reza Sharif-Afshar, M.D., Robert A Figlin, M.D., Hyung L Kim, M.D.
Ch. 25: Clinical Prognostic Factors in Metastatic Renal Cell Carcinoma
Nimira Alimohamed M.D., Toni K. Choueiri M.D., Daniel Y.C. Heng M.D.
Ch. 26: The Role of Advocacy in Renal Cell Carcinoma
William P. Bro, B.S.B., Paul Larson, M.S.
¿The third edition of this critically acclaimed book has updated and expanded the survey of clinical, biological and pathological management of localized and advanced renal cell carcinoma. Internationally renowned editors and contributors explore the latest developments in molecular genetics, focusing on the novel targets that have been discovered in epithelial renal tumors.
Comprehensive and authoritative, Renal Cell Carcinoma: Molecular Targets and Clinical Applications, Third Edition is the definitive text on the rapidly evolving landscape of experimental therapeutics, written and edited by leaders of the field.¿
Thoroughly updated edition focusing on new and recent developments in renal cell carcinoma
Provides updated information on the rapidly evolving field of renal cell carcinoma personalized medicine, with an emphasis on novel targets and therapy
Discusses the significant amount of new biologic and clinical information such as refinement of the RCC systemic treatment paradigm, immunoregulatory abnormalities in RCC, and adjuvant and neoadjuvant therapy¿